<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JBM</journal-id><journal-title-group><journal-title>Journal of Biosciences and Medicines</journal-title></journal-title-group><issn pub-type="epub">2327-5081</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jbm.2024.125006</article-id><article-id pub-id-type="publisher-id">JBM-133123</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  Nucleotide Contribution to the Functioning of SERT, Na&lt;sup&gt; &lt;/sup&gt;/K&lt;sup&gt; &lt;/sup&gt; ATPase and GPCR Proteins
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Wynford</surname><given-names>Robert Williams</given-names></name><xref ref-type="aff" rid="aff1"><sub>1</sub></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Faculty of Life Sciences &amp;amp; Education, University of South Wales, Cardiff, UK</addr-line></aff><pub-date pub-type="epub"><day>06</day><month>05</month><year>2024</year></pub-date><volume>12</volume><issue>05</issue><fpage>61</fpage><lpage>76</lpage><history><date date-type="received"><day>1,</day>	<month>April</month>	<year>2024</year></date><date date-type="rev-recd"><day>12,</day>	<month>May</month>	<year>2024</year>	</date><date date-type="accepted"><day>15,</day>	<month>May</month>	<year>2024</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Purine nucleotides are crucial for the effective operation of cell membrane proteins maintaining the neurotransmitter responses of 5-HT. Major protein targets in the treatment of depression include SERT, N/K ATPase and GPCR. Each protein target is responsive to a specific complement of drugs: antidepressants (SERT), lithium and cardiogenic steroids (N/K ATPase), 5-HT receptor ligands (GPCR). Computational software is useful for comparing molecular similarity within ligand-ligand and ligand-nucleotide structures. Previous studies demonstrate that GPCR ligands of different pharmacologic classes display relative molecular similarity to nucleotide structures. The current study applies this methodology to compound structures modulating SERT and N/K ATPase receptors. Minimum energy conformers of SERT antagonists demonstrate relative molecular similarity to the structural template of GTP nucleotide. GTP template fits of 5-HT and psilocin are similar, whereas a SERT-like fit is one of several for the ketamine structure. Endogenous and pharmaceutical modulators of Na/K ATPase relate to adenine nucleotide. The fits of cardiogenic steroids to a cGMP template demonstrate similarities and differences between compounds. Relative molecular similarity within the structures of hormones, drugs and nucleotides has implications for neurotransmitter transport and cell signal transduction processes.
 
</p></abstract><kwd-group><kwd>SERT</kwd><kwd> SSRI</kwd><kwd> GPCR</kwd><kwd> Sodium/Potassium ATPase</kwd><kwd> Nucleotides</kwd><kwd> Depression</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Therapeutic advances for depressive disorders have permitted a shift in focus from the use of tricyclic antidepressant (TCA) to SSRI (selective serotonin reuptake inhibitor) medication. Lithium remains a long-standing treatment for patients with bipolar disorder (BPD) or those requiring augmentation of medication [<xref ref-type="bibr" rid="scirp.133123-ref1">1</xref>] . Patient management problems, associated with therapeutic response times and refractory depression, have more recently stimulated interest in the use of ketamine and natural products based on psilocybin; both increase neurotransmitter levels in rat frontal cortex [<xref ref-type="bibr" rid="scirp.133123-ref2">2</xref>] . Progress in understanding the complex role of serotonin (5-HT) in maintaining mental health lags behind demonstration of the transmitter’s properties in the laboratory setting [<xref ref-type="bibr" rid="scirp.133123-ref3">3</xref>] . In reviewing the clinical effects of 5-HT, Carhart-Harris &amp; Nutt [<xref ref-type="bibr" rid="scirp.133123-ref4">4</xref>] consider two major serotonin brain transmission pathways based on 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptor subtypes; the former enhanced by SSRIs and the latter by psychodelic agonists. Regulation of the SERT (pre-synaptic plasma membrane serotonin transporter associated with Na<sup>+</sup> and Cl<sup>−</sup>) 5-HT transporter, however, involves the 5-HT<sub>2B</sub> receptor [<xref ref-type="bibr" rid="scirp.133123-ref5">5</xref>] .</p><p>SERT facilitates sodium- and chloride-dependent reuptake of neuron released 5-HT. SSRIs maintain tonic synapse concentrations of 5-HT by reducing removal via the protein transporter [<xref ref-type="bibr" rid="scirp.133123-ref5">5</xref>] . Central and vestibular binding sites on SERT are named respectively S1 and S2, with the latter designated as an allosteric site [<xref ref-type="bibr" rid="scirp.133123-ref6">6</xref>] . During the transport process, conformational changes in SERT alternately expose the central binding-site to extracellular or cytoplasmic media for substrate-binding or release [<xref ref-type="bibr" rid="scirp.133123-ref6">6</xref>] . Substrate and antagonists both target the primary binding-site of SERT. SERT proteins partition within plasma membrane lipid rafts; conformation and function are influenced by cholesterol [<xref ref-type="bibr" rid="scirp.133123-ref5">5</xref>] . Mutations in SERT are associated with psychiatric disorders and autism. Some mutations impacting on SERT activity influence the cGMP dependent phosphorylation of specific amino acid residues, a process initiated by conformational changes within the protein [<xref ref-type="bibr" rid="scirp.133123-ref7">7</xref>] .</p><p>Sodium ions initiate the cycle of conformational change within the SERT protein, which is an energy requiring process driven by the plasma membrane sodium/potassium ATPase (N/K ATPase) [<xref ref-type="bibr" rid="scirp.133123-ref8">8</xref>] . Although there is evidence of sodium channel inhibition by SSRIs [<xref ref-type="bibr" rid="scirp.133123-ref9">9</xref>] , lithium is the antidepressant most strongly associated with N/K ATPase modulation. Lithium normalises N/K ATPase activity and lipid peroxidation in blood samples from patients with BPD, and brain tissues of stressed rats [<xref ref-type="bibr" rid="scirp.133123-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.133123-ref11">11</xref>] . Lithium also augments 5-HT neurotransmission and SSRI treatment in animal and clinical settings [<xref ref-type="bibr" rid="scirp.133123-ref12">12</xref>] . Several endogenous compounds modulate 5-HT release from neurons. Histamine action (pre- and post-synaptically) inhibits 5-HT release; H<sub>3</sub> receptor antagonists are anxiolytic and antidepressive [<xref ref-type="bibr" rid="scirp.133123-ref13">13</xref>] . Thyronines show distinctive distribution patterns within the brain and allosteric effects on neurotransmitter receptors [<xref ref-type="bibr" rid="scirp.133123-ref14">14</xref>] . The N/K ATPase of the renal proximal tubule has an extracellular binding domain for cGMP, which inhibits Na<sup>+</sup> transport in a manner similar to the effects of ouabain [<xref ref-type="bibr" rid="scirp.133123-ref15">15</xref>] . Kidney medulla ATPase activity is modulated by fatty acid and acylglycerol compounds [<xref ref-type="bibr" rid="scirp.133123-ref16">16</xref>] .</p><p>In common with other neurotransmitters, 5-HT signaling is regulated intracellularly by G-proteins [<xref ref-type="bibr" rid="scirp.133123-ref17">17</xref>] . GTP nucleotide has a central role in the GPCR (G-protein coupled receptor) signaling process, which requires the cyclical regeneration of GTP-bound α proteins (Gα proteins). The Gα<sub>s</sub> protein induces cAMP generation, a nucleotide in brain tissue characterised by low levels in depressed patients and increased levels following antidepressant treatment [<xref ref-type="bibr" rid="scirp.133123-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.133123-ref19">19</xref>] . There has been increasing interest in the dimerisation of GPCR receptors in past decades, to the extent that this state may be considered as the norm for the expression and function of GPCRs [<xref ref-type="bibr" rid="scirp.133123-ref17">17</xref>] . Purine nucleotides therefore participate in regulating the responses of SSRI, SERT and N/K ATPase proteins and 5-HT signaling. Previous studies demonstrate molecular similarity within the structures of agonists and antagonists of different receptor classes, relative to the nucleotides of guanosine and adenosine. The present work seeks to extend this observation to the above modulators of depression with the aim of consolidating knowledge in regard to their mechanism of action.</p></sec><sec id="s2"><title>2. Material and Methods</title><sec id="s2_1"><title>2.1. Compound Structures</title><p>The compounds under investigation are SSRIs and inhibitors of SERT, as listed by the IUPHAR/BPS 2023. Guide to Pharmacology (https://www.guidetopharmacology.org). Additional compounds include the muco-active compound ambroxol, identified as an inhibitor of SERT in guinea pig colon [<xref ref-type="bibr" rid="scirp.133123-ref20">20</xref>] ; ibogaine is described as an active site-binding non-competitive inhibitor of SERT [<xref ref-type="bibr" rid="scirp.133123-ref21">21</xref>] ; MK-7145 is marketed by MedChemExpress (MCE; NJ 08852, USA) as a human SERT inhibitor in transinfected HEK293 cells. The chemicals for labelling SERT include ADAM ((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine) a high affinity SPECT (single photon emission computed tomography) tracer [<xref ref-type="bibr" rid="scirp.133123-ref22">22</xref>] and ASP (dimethylamino)styryl]-n-methylpyridinium) a fluorescent transporter substrate [<xref ref-type="bibr" rid="scirp.133123-ref23">23</xref>] . Arachidonic acid, monolaurin and dioctanoylglycerol are modulators of Na/K ATPase activity [<xref ref-type="bibr" rid="scirp.133123-ref16">16</xref>] . Compounds structures are taken from the PubChem website (https://pubchem.ncbi.nlm.nih.gov/).</p></sec><sec id="s2_2"><title>2.2. Molecular Modeling</title><p>Compound structures are built from contents of the Nemesis software program fragment file (Oxford Molecular version 2.1) and minimised by conformational analysis. The molecular structures used for fitting are minimum energy conformers in an uncharged form. The conformation of the cGMP structure is described by the torsion angle (bond angle described by 4 adjacent atoms) C8N9C1’O9 −33˚ (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The same torsion angle in the GTP and ATP structures are respectively −47˚ and −38˚. The Nemesis program fits paired molecular structures on a three-point basis. Fitting-points, comprised of atoms of similar type and partial charge within compound and nucleotide structures, are identified in the text and table with respect to the nucleotide labels. Colour-coded atoms in the</p><p>figures identify ligand fitting-points: carbon-green, nitrogen-blue, oxygen-red, sulphur-yellow. To improve on presentation of the fitted compounds, bond order within molecular structures is not shown and the triphosphate chain of GTP is cropped. The Nemesis program computes goodness-of-fit values, in respect of inter-atomic distance at each fitting-point and root mean square (RMS) value. The sequence of fitting points for each structure (given in <xref ref-type="table" rid="table1">Table 1</xref>, left to right) provides the fit with the lowest RMS value.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Values for fitting compound structures to nucleotide templates</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Compound</th><th align="center" valign="middle" >Nucleotide</th><th align="center" valign="middle" >Fitting points</th><th align="center" valign="middle" >Interatomic distance (&#197;)</th><th align="center" valign="middle" >RMS (&#197;)</th></tr></thead><tr><td align="center" valign="middle" >5-HT</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C2C4C6</td><td align="center" valign="middle" >0.06, 0.07, 0.01</td><td align="center" valign="middle" >0.0049</td></tr><tr><td align="center" valign="middle" >5-HT</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C8N7C2</td><td align="center" valign="middle" >0.05, 0.02, 0.05</td><td align="center" valign="middle" >0.0022</td></tr><tr><td align="center" valign="middle" >5-HT</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >N7C5C1’</td><td align="center" valign="middle" >0.01, 0.00, 0.01</td><td align="center" valign="middle" >0.0002</td></tr><tr><td align="center" valign="middle" >ADAM</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C2C4C5</td><td align="center" valign="middle" >0.05, 0.06, 0.02</td><td align="center" valign="middle" >0.0068</td></tr><tr><td align="center" valign="middle" >ambroxol</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C2C4C5</td><td align="center" valign="middle" >0.06, 0.04, 0.03</td><td align="center" valign="middle" >0.0010</td></tr><tr><td align="center" valign="middle" >arachadonic acid</td><td align="center" valign="middle" >ATP</td><td align="center" valign="middle" >C5C1C2’</td><td align="center" valign="middle" >0.11, 0.12, 0.05</td><td align="center" valign="middle" >0.0033</td></tr><tr><td align="center" valign="middle" >bufalin</td><td align="center" valign="middle" >cGMP</td><td align="center" valign="middle" >C4C2’O9</td><td align="center" valign="middle" >0.04, 0.03, 0.07</td><td align="center" valign="middle" >0.0066</td></tr><tr><td align="center" valign="middle" >carbamazepine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C8N9C1</td><td align="center" valign="middle" >0.04, 0.05, 0.06</td><td align="center" valign="middle" >0.0112</td></tr><tr><td align="center" valign="middle" >carbamazepine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C6N1C2</td><td align="center" valign="middle" >0.01, 0.01, 0.02</td><td align="center" valign="middle" >0.0021</td></tr><tr><td align="center" valign="middle" >cocaine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C2C4C5</td><td align="center" valign="middle" >0.06, 0.04, 0.03</td><td align="center" valign="middle" >0.0010</td></tr><tr><td align="center" valign="middle" >cocaine</td><td align="center" valign="middle" >cGMP</td><td align="center" valign="middle" >C6N1C1’</td><td align="center" valign="middle" >0.06. 0.07, 0.06</td><td align="center" valign="middle" >0.0001</td></tr><tr><td align="center" valign="middle" >dapoxetine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C2C4C5</td><td align="center" valign="middle" >0.07, 0.06, 0.03</td><td align="center" valign="middle" >0.0056</td></tr><tr><td align="center" valign="middle" >digitoxigenin</td><td align="center" valign="middle" >cGMP</td><td align="center" valign="middle" >O9C1’C4</td><td align="center" valign="middle" >0.04, 0.09, 0.08</td><td align="center" valign="middle" >0.0159</td></tr><tr><td align="center" valign="middle" >1,2-dioctanoylglycerol</td><td align="center" valign="middle" >ATP</td><td align="center" valign="middle" >C1’N9C5</td><td align="center" valign="middle" >0.02, 0.09, 0.10</td><td align="center" valign="middle" >0.0023</td></tr><tr><td align="center" valign="middle" >escitalopram</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C5C6C2</td><td align="center" valign="middle" >0.02, 0.03, 0.04</td><td align="center" valign="middle" >0.0003</td></tr><tr><td align="center" valign="middle" >fluvoaxamine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C2C4C5</td><td align="center" valign="middle" >0.07, 0.04, 0.04</td><td align="center" valign="middle" >0.0017</td></tr><tr><td align="center" valign="middle" >ibogaine</td><td align="center" valign="middle" >cGMP</td><td align="center" valign="middle" >C4’C3’N1</td><td align="center" valign="middle" >0.06, 0.05, 0.02</td><td align="center" valign="middle" >0.0006</td></tr><tr><td align="center" valign="middle" >ibogaine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C2C4C5</td><td align="center" valign="middle" >0.04, 0.04, 0.01</td><td align="center" valign="middle" >0.0013</td></tr><tr><td align="center" valign="middle" >immepip</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C8N1C2</td><td align="center" valign="middle" >0.02, 0.04, 0.06</td><td align="center" valign="middle" >0.0042</td></tr><tr><td align="center" valign="middle" >(S)-ketamine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >N9C1’C2’</td><td align="center" valign="middle" >0.05, 0.08, 0.04</td><td align="center" valign="middle" >0.0167</td></tr><tr><td align="center" valign="middle" >(S)-ketamine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C4N9C2’</td><td align="center" valign="middle" >0.10, 0.07, 0.03</td><td align="center" valign="middle" >0.0046</td></tr><tr><td align="center" valign="middle" >(S)-ketamine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >O6C6C5</td><td align="center" valign="middle" >0.01, 0.05, 0.06</td><td align="center" valign="middle" >0.0052</td></tr><tr><td align="center" valign="middle" >(S)-ketamine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >N1C2N3</td><td align="center" valign="middle" >0.07, 0.09, 0.03</td><td align="center" valign="middle" >0.0086</td></tr><tr><td align="center" valign="middle" >(S)-ketamine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C1’N9C8</td><td align="center" valign="middle" >0.05, 0.06, 0.03</td><td align="center" valign="middle" >0.0109</td></tr><tr><td align="center" valign="middle" >(S)-ketamine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C5C4C2</td><td align="center" valign="middle" >0.04, 0.03, 0.06</td><td align="center" valign="middle" >0.0004</td></tr><tr><td align="center" valign="middle" >(S)-ketamine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C2’C1’N9</td><td align="center" valign="middle" >0.05, 0.08, 0.05</td><td align="center" valign="middle" >0.0018</td></tr><tr><td align="center" valign="middle" >levomilnacipran</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C2’C1’C8</td><td align="center" valign="middle" >0.03, 0.05, 0.07</td><td align="center" valign="middle" >0.0136</td></tr><tr><td align="center" valign="middle" >levomilnaipran</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C2C4C5</td><td align="center" valign="middle" >0.06, 0.04, 0.02</td><td align="center" valign="middle" >0.0000</td></tr><tr><td align="center" valign="middle" >methylene blue</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C2C4C5</td><td align="center" valign="middle" >0.07, 0.05, 0.04</td><td align="center" valign="middle" >0.0035</td></tr><tr><td align="center" valign="middle" >mirtazapine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C5C4C2</td><td align="center" valign="middle" >0.02, 0.01, 0.02</td><td align="center" valign="middle" >0.0007</td></tr><tr><td align="center" valign="middle" >MK-7145</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C2C4C5</td><td align="center" valign="middle" >0.03, 0.03, 0.02</td><td align="center" valign="middle" >0.0037</td></tr><tr><td align="center" valign="middle" >1-monolauroylglycerol</td><td align="center" valign="middle" >ATP</td><td align="center" valign="middle" >C1’N9C5</td><td align="center" valign="middle" >0.02, 0.09, 0.09</td><td align="center" valign="middle" >0.0009</td></tr><tr><td align="center" valign="middle" >ouabain</td><td align="center" valign="middle" >cGMP</td><td align="center" valign="middle" >O9C2’C4</td><td align="center" valign="middle" >0.06, 0.05, 0.03</td><td align="center" valign="middle" >0.0016</td></tr><tr><td align="center" valign="middle" >ouabain</td><td align="center" valign="middle" >cGMP</td><td align="center" valign="middle" >N9C1’O8</td><td align="center" valign="middle" >0.11, 0.02, 0.10</td><td align="center" valign="middle" >0.0052</td></tr><tr><td align="center" valign="middle" >ouabain</td><td align="center" valign="middle" >cGMP</td><td align="center" valign="middle" >C2’C1’N9</td><td align="center" valign="middle" >0.08, 0.04, 0.10</td><td align="center" valign="middle" >0.0143</td></tr><tr><td align="center" valign="middle" >ouabain</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >N2C6C4</td><td align="center" valign="middle" >0.06, 0.09, 0.13</td><td align="center" valign="middle" >0.0071</td></tr><tr><td align="center" valign="middle" >paroxetine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C2C4C5</td><td align="center" valign="middle" >0.04, 0.05, 0.02</td><td align="center" valign="middle" >0.0072</td></tr><tr><td align="center" valign="middle" >propafenone</td><td align="center" valign="middle" >ATP</td><td align="center" valign="middle" >O9C1’C8</td><td align="center" valign="middle" >0.05, 0.01, 0.04</td><td align="center" valign="middle" >0.0109</td></tr><tr><td align="center" valign="middle" >protriptyline</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C8N9C1’</td><td align="center" valign="middle" >0.08, 0.08, 0.01</td><td align="center" valign="middle" >0.0019</td></tr><tr><td align="center" valign="middle" >psilocin (13)</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C5C4C2</td><td align="center" valign="middle" >0.02, 0.03, 0.04</td><td align="center" valign="middle" >0.0019</td></tr><tr><td align="center" valign="middle" >psilocin (14)</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C5C4C2</td><td align="center" valign="middle" >0.05, 0.03, 0.08</td><td align="center" valign="middle" >0.0016</td></tr><tr><td align="center" valign="middle" >psilocybin</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C5C4C2</td><td align="center" valign="middle" >0.02, 0.04, 0.03</td><td align="center" valign="middle" >0.0048</td></tr><tr><td align="center" valign="middle" >QX314</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C8N9C1’</td><td align="center" valign="middle" >0.05, 0.02, 0.06</td><td align="center" valign="middle" >0.0077</td></tr><tr><td align="center" valign="middle" >QX314</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C6N1C2</td><td align="center" valign="middle" >0.02, 0.01, 0.01</td><td align="center" valign="middle" >0.0017</td></tr><tr><td align="center" valign="middle" >rostafuroxin</td><td align="center" valign="middle" >cGMP</td><td align="center" valign="middle" >C4C2’O9</td><td align="center" valign="middle" >0.02, 0.05, 0.06</td><td align="center" valign="middle" >0.0104</td></tr><tr><td align="center" valign="middle" >sealdin</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C5C6N2</td><td align="center" valign="middle" >0.10, 0.05, 0.09</td><td align="center" valign="middle" >0.0029</td></tr><tr><td align="center" valign="middle" >triiodothyronine (T3)</td><td align="center" valign="middle" >ATP</td><td align="center" valign="middle" >C5C6C3’</td><td align="center" valign="middle" >0.05, 0.07, 0.05</td><td align="center" valign="middle" >0.0066</td></tr><tr><td align="center" valign="middle" >trazon</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >N3C2N1</td><td align="center" valign="middle" >0.07, 0.01, 0.08</td><td align="center" valign="middle" >0.0058</td></tr><tr><td align="center" valign="middle" >trazon</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >N9C4C5</td><td align="center" valign="middle" >0.02, 0.07, 0.07</td><td align="center" valign="middle" >0.0075</td></tr><tr><td align="center" valign="middle" >thioperamide</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C2N3N9</td><td align="center" valign="middle" >0.03, 0.07, 0.04</td><td align="center" valign="middle" >0.0120</td></tr><tr><td align="center" valign="middle" >triamterene</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >N7C8C1’</td><td align="center" valign="middle" >0.03, 0.03, 0.02</td><td align="center" valign="middle" >0.0072</td></tr><tr><td align="center" valign="middle" >triamterene</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C6C2N3</td><td align="center" valign="middle" >0.03, 0.03, 0.04</td><td align="center" valign="middle" >0.0039</td></tr><tr><td align="center" valign="middle" >tripelennamine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C5C4C2</td><td align="center" valign="middle" >0.02, 0.04, 0.05</td><td align="center" valign="middle" >0.0040</td></tr><tr><td align="center" valign="middle" >vortioxetine</td><td align="center" valign="middle" >GTP</td><td align="center" valign="middle" >C2C4C5</td><td align="center" valign="middle" >0.06, 0.05, 0.02</td><td align="center" valign="middle" >0.0042</td></tr></tbody></table></table-wrap></sec></sec><sec id="s3"><title>3. Results</title><p>Three fits of the minimum energy 5-HT conformer to the GTP structure are given in <xref ref-type="fig" rid="fig1">Figure 1</xref> (2 - 4), followed by those of compounds regarded as sodium channel blockers (6 - 12). Protriptyline and carbamazepine are tricyclic compounds with antidepressant and anticonvulsant uses, respectively. QX314 has local anaesthetic properties, whereas triamterene is a diuretic. These drug structures have fitting-points on the imidazole and ribose rings of the GTP template (6, 7, 8) and a second fit on the oxopyrimidine moiety involving C6, N1, C2/N3 atoms (10, 11, 12). Trazon (5), a SSRI and antidepressant, has a structure small enough to provide two non-overlapping fits on the guanine ring. One feature common to the remaining SSRI structures (13 - 20) and the previous antagonist structures in this figure, is the presence of substantial substituent groups of cyclic rings or alkyl-amino sidechains, in the 9 - 11 o’clock position with respect to imidazole atom N9. Distances between fitting-point C2 and the distal substituent atom range from 6.9&#197; (mirtazapine) to 11.8&#197; (paroxetine), with ADAM, sealdin, dapoxetine, ambroxol and fluvoxamine of the fitted structures providing values in-between, in ascending order. In contrast, the fitted SERT substrate (5-HT) has no bulky structure to extend into the space occupied by the SSRI inhibitors. The fit of one SSRI/SERT inhibitor thus covers approximately the same area as the double fit of a sodium channel blocker structure.</p><p><xref ref-type="fig" rid="fig2">Figure 2</xref> extends the number of SSRI/SERT structures fitted on the GTP template (1 - 7). As in the previous figure, the structures feature a bulky substituent group in the 9 - 11 o’clock position. ADAM is a tracer compound with high affinity for SERT, whereas vortioxetine is in use as an antidepressant. A SSRI/SERT-like fit is also given for ouabain (8). Immepip (9) and thioperamide (10), respectively H<sub>3</sub>/H<sub>4</sub> receptor agonist and antagonist compounds, provide fits to the GTP template that differ from the SSRI/SERT compounds in that their imidazole rings provide only 2 fitting points on the nucleotide oxopyrimidine ring. The fits of methylene blue (11) (an antidepressant and guanylate cyclase inhibitor) and the fluorescent substrate ASP are similar to those of the SSRI/SERT inhibitors. Template 12 gives the superimposition of ASP on the methylene blue structure (grey), demonstrating their similarity. Fitting-point values of SSRI/SERT inhibitor structures on GTP are mostly less than 0.1&#197;, (<xref ref-type="table" rid="table1">Table 1</xref>) and RMS values are &lt;0.02&#197;. The nucleotide template fits of psilocin and psilocybin structures (13 - 15) are more similar to those of 5-HT. In keeping with the disparate properties of ketamine, the minimum energy conformer demonstrates several fits to the GTP template (16 - 22), including one (21) comparable to those of SSRI/SERT inhibitors.</p><p>The SERT transporter operates using energy produced by Na/K ATPase activity. Compound structures in <xref ref-type="fig" rid="fig3">Figure 3</xref> (1 - 5) fit to a low energy conformer of ATP that illustrates the potential for interaction with the the nucleotide triphosphate chain, substrate of the ATPase. Arachidonic acid (1), propafenone (2) and triiodothyronine (T3) (3) are activators of Na/K ATPase. Monolauroylglycerol (4) is also an activator, whereas dioctanoylglycerol (5) is an inhibitor of the ATPase. cGMP, a nucleotide regulator of Na/K ATPase, provides the fitting template for the structures of ibogaine (6), cocaine (7) and cardiac steroids (8 - 12). Fits of the inhibitor ouabain (8, 9), based on the steroid nucleus, are replicated by bufalin (11), rostafuroxin (12) and digitoxigenin (not shown). These steroid structures do not replicate the ouabain fit of template 10 because they lack a sugar moiety. Template 13 demonstrates relative molecular similarity in a composite fit (based on template 8) of the 4 steroid structures without the nucleotide. The fitting data of compound structures in <xref ref-type="fig" rid="fig3">Figure 3</xref> are comparable to those of the SSRI/SERT inhibitors (<xref ref-type="table" rid="table1">Table 1</xref>).</p></sec><sec id="s4"><title>4. Discussion</title><p>SERT inhibitor structures demonstrate molecular similarity to GTP nucleotide, in respect of the fit of an aromatic or cyclic ring and the distant positioning of bulky substituent groups that do not contain the template fitting-points. The structures of tricyclic sodium channel blockers relate to the GTP template but with a different fitting pattern. Baudry and co-authors [<xref ref-type="bibr" rid="scirp.133123-ref5">5</xref>] describe the concentration dependent uptake of 5-HT by SERT via the 5-HT<sub>2B</sub> receptor, regulated by NOS/PKG (low 5-HT) or PKC (high 5-HT) signalling processes and phosphorylation. Both SERT and N/K ATPase proteins are subject to a phosphorylation process, which is reproduced in vitro by the relevant second messengers [<xref ref-type="bibr" rid="scirp.133123-ref24">24</xref>] . Hyperphosphorylation of these proteins reduces 5-HT uptake and antidepressant binding to SERT. SERT phosphorylation and transport activity is rapidly regulated in vitro by agonists and antagonists of protein kinases, notably PKC, PKG, and p38MAPK. The 5-HT<sub>2B</sub> receptor controls the phosphorylation sites of SERT and N/K ATPase and the change in default coupling from PKG to PKC, resulting in hyperphosphorylation, provides an important intervention target for correction [<xref ref-type="bibr" rid="scirp.133123-ref5">5</xref>] . On the outward-open conformation of SERT an assembly complex of substrate and bound Na<sup>+</sup> initiates uptake of 5-HT; transport is not sustained by other monovalent ions [<xref ref-type="bibr" rid="scirp.133123-ref8">8</xref>] . The molecular structures of antidepressants wedge between the membrane-anchored scaffold domain and the mobile domain of outward-facing SERT [<xref ref-type="bibr" rid="scirp.133123-ref25">25</xref>] . Cocaine and Na<sup>+</sup> stabilise the outward-open conformation of SERT and decrease phosphorylation, whereas compounds that stabilise inward-open conformations (5-HT and ibogaine) increase phosphorylation. The differences between the template-fitted substrate and inhibitor structures suggest that the bulky substituent groups of the latter are responsible for preventing the occlusion of SERT, which is a necessary first step in the transporter process. The IUPHAR/BPS database lists protriptyline as an inhibitor of SERT whereas tripelennamine and mirtazapine are listed as SSRI drugs. Escitalopram, paroxetine and fluvoxamine are listed as both SERT and SSRI drugs. This class distinction between SERT inhibitors and SSRI is of unlikely significance.</p><p>Histamine H<sub>3</sub>/H<sub>4</sub> receptor agonists reduce SERT phosphorylation and activity in rat hippocampal synaptosomes [<xref ref-type="bibr" rid="scirp.133123-ref13">13</xref>] . Antagonism by thioperamide and the failure to repeat these observations in cells devoid of histamine receptors indicates that histamine modulates 5-HT function on 5-HT neurons. In regard to the nucleotide template fits of these compounds, the imidazole ring of histamine derivatives appears to be a sufficient replacement for a six-membered carbon ring, evident in the psilocin and psilocybin template fits to 5-HT. Psilocin is a SERT inhibitor in rat brain synaptosomes but has greater affinity as an agonist of 5-HT<sub>2A</sub> receptors [<xref ref-type="bibr" rid="scirp.133123-ref26">26</xref>] . A recent systematic review of psilocybin treatment of depression reports a lack of consensus between studies [<xref ref-type="bibr" rid="scirp.133123-ref27">27</xref>] . Ketamine inhibition of 5-HT transport is lost in a mouse strain lacking the transporter protein [<xref ref-type="bibr" rid="scirp.133123-ref28">28</xref>] . Positron emission tomography measurements in monkeys following sub-lethal doses of ketamine identify transient inhibition of SERT activity [<xref ref-type="bibr" rid="scirp.133123-ref29">29</xref>] . Ketamine promotes plasticity in the hippocampus, via a negative synaptic feedback response expressed by a subtype of AMPA receptor [<xref ref-type="bibr" rid="scirp.133123-ref30">30</xref>] . Inhibition of NMDA receptors on GABAergic interneurons leads to disinhibition and activation of AMPA receptor pathways [<xref ref-type="bibr" rid="scirp.133123-ref31">31</xref>] . The pleiotropic nature of ketamine [<xref ref-type="bibr" rid="scirp.133123-ref32">32</xref>] is evident in this study by the different fits provided by its minimum energy conformer on the GTP template, which include those characteristic of SERT, glycine, GABA, NMDA, kainate and AMPA ligands (see Williams 2018, <xref ref-type="fig" rid="fig2">Figure 2</xref>) [<xref ref-type="bibr" rid="scirp.133123-ref33">33</xref>] . The wide spectrum of effects on cells produced by low ketamine concentrations, including oxidative stress and apoptosis, is of some concern in the clinical context [<xref ref-type="bibr" rid="scirp.133123-ref34">34</xref>] .</p><p>The sodium channel blocking effects of antidepressants may also relate to their effects on ATPase activity. Imipramine and fluoxetine decrease rat synaptic plasma membrane N/K ATPase in vitro [<xref ref-type="bibr" rid="scirp.133123-ref35">35</xref>] . The neurotransmitter-like interaction of thyroxine with ATP associated enzyme systems has long been of interest. An inverse relationship between thyroxine activation of adenyl cyclase and N/K ATPase activity is observed in cat heart homogenates and rat synaptosomal membranes [<xref ref-type="bibr" rid="scirp.133123-ref36">36</xref>] . Protein kinase phosphorylation of the catalytic alpha unit, containing ATP and ouabain binding sites, modulates ATPase pump activity [<xref ref-type="bibr" rid="scirp.133123-ref37">37</xref>] . The release of the neurotransmitters norepinephrine and 5-HT and their effects on N/K ATPase activity may be subject to reciprocal control [<xref ref-type="bibr" rid="scirp.133123-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.133123-ref38">38</xref>] . Among other compounds modulating N/K ATPase are long chain fatty acids and glycerol derivatives. Fatty acids have inhibitory and stimulatory effects on purified preparations of Na/K ATPase, depending on the ATP concentration [<xref ref-type="bibr" rid="scirp.133123-ref16">16</xref>] . Under the same experimental conditions, monoacylglycerols activate transport and hydrolytic functions of the enzyme and are antagonised by diacylglycerols. Propafenone, an antiarrhythmic drug, stimulates P-glycoprotein ATPase activity in intact cells and vesicles, a property strongly associated with lipophilicity [<xref ref-type="bibr" rid="scirp.133123-ref39">39</xref>] . In regard to ATP nucleotide template fits, the structures of arachidonic acid, propafenone and T3 relate to their properties of promoting ATPase function. The template fits of the mono- and di-glycerides structures with their distinctive alignment of alkyl chains characterise their stimulatory and inhibitory effects on ATPase function.</p><p>Ouabain and digoxin are potent inhibitors of 5-HT uptake by human platelets [<xref ref-type="bibr" rid="scirp.133123-ref40">40</xref>] , an observation that concurs with inhibition of the N/K ATPase and the SERT-like fit of ouabain to the GTP template. Ouabain modulates N/K ATPase from the extracellular side, triggering Ca<sup>2+</sup> release from intracellular stores, whereas digitalis glycosides act intracellularly on ryanodine receptors [<xref ref-type="bibr" rid="scirp.133123-ref41">41</xref>] . The rhamnose and lactone moieties of ouabain are essential for N/K ATPase inhibition, whereas hypertensive properties relate to the steroid nucleus. The functional properties of cGMP and ouabain are inhibited by the ouabain antagonist rostafuroxin, which does not inhibit N/K ATPase [<xref ref-type="bibr" rid="scirp.133123-ref42">42</xref>] . The fitting data in this study depict general template fits of bufalin, rostafuroxin and ouabain involving the steroid nucleus and one specific fit of ouabain involving the sugar linkage. cGMP is natriuretic and molecular modelling demonstrates a potential cGMP docking site in the ouabain-binding pocket of the renal proximal tubule N/K ATPase [<xref ref-type="bibr" rid="scirp.133123-ref15">15</xref>] . cGMP inhibits N/K ATPase in a similar manner to ouabain and both promote phosphorylation. Several models consider the intracellular signaling effects of cardiotonic steroids on N/K ATPase, in terms of reactive oxygen species, reactive nitrogen species and intracellular ionic changes [<xref ref-type="bibr" rid="scirp.133123-ref43">43</xref>] . Intracerebroventricular administration of ouabain to rats provides a model of BPD demonstrating manic and depressive states, decreased N/K ATPase activity, changes in the HPA axis, oxidative stress and the abrogation of such changes by lithium [<xref ref-type="bibr" rid="scirp.133123-ref44">44</xref>] . There is evidence that lithium modulates nucleotide cyclase activity and second-messenger systems impacting on cell signal transduction [<xref ref-type="bibr" rid="scirp.133123-ref45">45</xref>] . Differences in the nature of sodium and lithium ions mean that Li+ achieves a higher conductance through ion channels and neuronal membranes, attributable to its smaller mass [<xref ref-type="bibr" rid="scirp.133123-ref46">46</xref>] . The benefits of lithium in mouse models of anxiety and seizure are augmented by inhibitors (L-NAME and methylene blue) of NOS and guanylate cyclase [<xref ref-type="bibr" rid="scirp.133123-ref47">47</xref>] [<xref ref-type="bibr" rid="scirp.133123-ref48">48</xref>] . Methylene blue decreases 5-HT uptake by SERT, inhibits ion currents initiated by 5-HT and reduces binding of ASP (used for real-time monitoring of transporter function in single cells) [<xref ref-type="bibr" rid="scirp.133123-ref49">49</xref>] . The potential for interaction between methylene blue and ASP is evident in their their GTP template fits.</p><p>Activation of SERT and GPCR are both accompanied by extensive conformational changes within their constituent protein units and the cell membrane. The actions of antidepressants, including ketamine, are characterised by an increase in cAMP and the redistribution of the Gα<sub>s</sub> protein from lipid rafts to more fluid regions of the cell membrane, and disruption of Gα<sub>s</sub> /tubulin complexes enabling activation of adenyl cyclase signaling [<xref ref-type="bibr" rid="scirp.133123-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.133123-ref50">50</xref>] . The competition of receptor agonists, antagonists and antidepressant compounds with radiolabeled [35S]-GTPγ<sub>s</sub> for dorsal raphe neuron 5-HT receptors [<xref ref-type="bibr" rid="scirp.133123-ref51">51</xref>] provides supporting evidence for the antidepressant desensitisation of presynaptic 5-HT<sub>1A</sub> receptors and SSRI therapy. Studies based on crystallography, spectroscopy and computer simulation demonstrate the functional complexity of GPCRs and serve to develop cell-signaling models [<xref ref-type="bibr" rid="scirp.133123-ref52">52</xref>] . In contrast, the relative molecular similarity within ligand structures of SERT and GPCR proteins demonstrates a remarkable simplicity based on the structure of GTP. In regard to the molecular basis of GPCR signaling, receptor ligand and GTP structures contain equivalent core pharmacophores, representing common extracellular and intracellular codes; dimeric receptor messages that may serve as specific activation and transmission mechanisms of Gα proteins.</p></sec><sec id="s5"><title>5. Conclusion</title><p>In conclusion, the necessary co-operation between SERT and N/K ATPase in achieving 5-HT homeostasis is markedly dependent on attaining correct protein phosphorylation levels. Malfunction of this mechanism is improved by endogenous and synthetic compounds with properties dependent on their molecular similarity to purine nucleotide structure.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The author declares no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Williams, W.R. (2024) Nucleotide Contribution to the Functioning of SERT, Na<sup>+</sup>/K<sup>+</sup> ATPase and GPCR Proteins. Journal of Biosciences and Medicines, 12, 61-76. https://doi.org/10.4236/jbm.2024.125006</p></sec></body><back><ref-list><title>References</title><ref id="scirp.133123-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Malhi, G.S. and Mann, J.J. (2018) Depression. &lt;i&gt;The Lancet&lt;/i&gt;, 392, 2299-2312.&lt;br&gt;https://doi.org/10.1016/S0140-6736(18)31948-2</mixed-citation></ref><ref id="scirp.133123-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Wojtas, A., Bysiek, A., Wawrzczak-Bargiela, A., Szych, Z., Majcher-Maslanka, I., Herian, M., Mackowiak, M. and Golembiowska, K. (2022) Effect of Psilocybin and Ketamine on Brain Neurotransmitters, Glutamate Receptors, DNA and Rat Behaviour. &lt;i&gt;International Journal of Molecular Sciences&lt;/i&gt;, 23, Article 6713.&lt;br&gt;https://doi.org/10.3390/ijms23126713</mixed-citation></ref><ref id="scirp.133123-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Moncrieff, J., Cooper, R.E., Stoakmann, T., Amendola, S., Hengartner, M.P. and Horowitz, M.A. (2022) The Serotonin Theory of Depression: A Systematic Umbrella Review of the Evidence. &lt;i&gt;Molecular Psychiatry&lt;/i&gt;, 28, 3243-3256.&lt;br&gt;https://doi.org/10.1038/s41380-022-01661-0</mixed-citation></ref><ref id="scirp.133123-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Carhart-Harris, R.L. and Nutt, D.J. (2017) Serotonin and Brain Function: A Tale of Two Receptors. &lt;i&gt;Journal of Psychopharmacology&lt;/i&gt;, 31, 1091-1120. &lt;br&gt;https://doi.org/10.1177/0269881117725915</mixed-citation></ref><ref id="scirp.133123-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Baudry, A., Pietri, M., Launay, J.M., Kellermann, O. and Schneider, B. (2019) Multifaceted Regulations of the Serotonin Transporter: Impact on Antidepressant Response. &lt;i&gt;Frontiers in Neuroscience&lt;/i&gt;, 13, Article 91. &lt;br&gt;https://doi.org/10.3389/fnins.2019.00091</mixed-citation></ref><ref id="scirp.133123-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Zeppelin, T., Ladefoged, L.K., Sinning, S. and Schiott, B. (2019) Substrate and Inhibitor Binding to the Serotonin Transporter: Insights from Computational, Crystallographic, and Functional Studies. &lt;i&gt;Neuropharmacology&lt;/i&gt;, 161, Article 107548. &lt;br&gt;https://doi.org/10.1016/j.neuropharm.2019.02.030</mixed-citation></ref><ref id="scirp.133123-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y.W., Turk, B.E. and Rudnick, G. (2016) Control of Serotonin Transporter Phosphorylation by Conformational State. &lt;i&gt;Proceedings of the National Academy of Sciences USA&lt;/i&gt;, 113, E2276-E2783. &lt;br&gt;https://www.pnas.org/cg/doi/10.1073/Pnas.160328113&lt;br&gt;https://doi.org/10.1073/pnas.1603282113</mixed-citation></ref><ref id="scirp.133123-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Szollosi, D. and Stockner, T. (2021) Investigating the Mechanism of Sodium Binding to SERT Using Direct Simulations. &lt;i&gt;Frontiers in Cellular Neuroscience&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;15, Article 673782. &lt;br&gt;https://doi.org/10.3389/fncel.2021.673782</mixed-citation></ref><ref id="scirp.133123-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Plijter, I., Verkerk, A.O. and Wilders, R. (2023) The Antidepressant Drug Paroxetine Reduces the Cardiac Sodium Channel.&lt;i&gt; International Journal of Molecular &lt;/i&gt;&lt;i&gt;Sciences&lt;/i&gt;, 24, Article 1904. &lt;br&gt;https://doi.org/10.3390/ijms24031904</mixed-citation></ref><ref id="scirp.133123-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Banerjee, U., Dasgupta, A., Rout, J.K. and Singh, O.P. (2012) Effects of Lithium Therapy on Na&lt;sup&gt; &lt;/sup&gt;-K&lt;sup&gt; &lt;/sup&gt;-ATPase Activity and Lipid Peroxidation in Bipolar Disorder. &lt;i&gt;Progress in Neuro&lt;/i&gt;-&lt;i&gt;Psychopharmacology and Biological Psychiatry&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;37, 56-61.&lt;br&gt;https://doi.org/10.1016/j.pnpbp.2011.12.006</mixed-citation></ref><ref id="scirp.133123-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Vosahlikova, M., Roubalova, L., Cechova, K., Kaufman, J., Musil, S., Miksik, I., Alda, M. and Svoboda, P. (2020) Na&lt;sup&gt; &lt;/sup&gt;/K&lt;sup&gt; &lt;/sup&gt;-ATPase and Lipid Peroxidation in Forebrain Cortex and Hippocampus of Sleep-Deprived Rats Treated with Therapeutic Lithium Concentration for Different Periods of Time. &lt;i&gt;Progress in Ne&lt;/i&gt;&lt;i&gt;u&lt;/i&gt;&lt;i&gt;ro&lt;/i&gt;-&lt;i&gt;Psychopharmacology and Biological Psychiatry&lt;/i&gt;, 102, Article 109953. &lt;br&gt;https://doi.org/10.1016/j.pnpbp.2020.109953</mixed-citation></ref><ref id="scirp.133123-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Bauer, M., Adli, M., Bschor, T., Pilhatsch, M., Pfennig, A., Sasse, J., Schmid, R. and Lewitzka, U. (2010) Lithium&amp;#8217;s Emerging Role in the Treatment of Refractory Major Depressive Episodes: Augmentation of Antidepressants. &lt;i&gt;Neuropsychobiology&lt;/i&gt;, 62, 36-42. &lt;br&gt;https://doi.org/10.1159/000314308</mixed-citation></ref><ref id="scirp.133123-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Annamalai, B., Varma, D.R., Horton, R.E., Daws, L.C., Jayanthi, L.D. and Ramamoorthy, S. (2020) Histamine Receptors Regulate the Activity, Surface Expression and Phosphorylation of Serotonin Transporters. &lt;i&gt;ACS Chemical Neuroscience&lt;/i&gt;, 11, 466-476. &lt;br&gt;https://doi.org/10.1021/acschemneuro.9b00664</mixed-citation></ref><ref id="scirp.133123-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Martin, J.V. and Sakar, P.K. (2023) Nongenomic Roles of Thyroid Hormones and Their Derivatives in Adult Brain: Are These Compounds Putative Neurotransmitters? &lt;i&gt;Frontiers in Endocrinology&lt;/i&gt;, 14, Article 1210540. &lt;br&gt;https://doi.org/10.3389/fendo.2023.1210540</mixed-citation></ref><ref id="scirp.133123-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kemp, B.A., Howell, N.L., Gildea, J.J., Hinkle, J.D., Shabanowitz, J., Hunt, D.F., Conaway, M.R., Keller, S.R. and Carey, R.M. (2023) Evidence that Binding of Cyclic GMP to the Extracellular Domain of NKA (Sodium-Potassium ATPase) Mediates Natriuresis.&lt;i&gt; Circulation Research&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;132, 1127-1140.&lt;br&gt;https://doi.org/10.1161/CIRCRESAHA.122.321693</mixed-citation></ref><ref id="scirp.133123-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Jack-Hays, M.G., Xie, Z., Wang, Y., Huang, W.H. and Askari, A. (1996) Activation of Na&lt;sup&gt; &lt;/sup&gt;/K&lt;sup&gt; &lt;/sup&gt;-ATPase by Fatty Acids, Acylglycerols, and Related Amphiphiles: Structure-Activity Relationship. &lt;i&gt;Biochemica et Biophysica Acta&lt;/i&gt;-&lt;i&gt;Biomembranes&lt;/i&gt;, 1279, 43-48. &lt;br&gt;https://doi.org/10.1016/0005-2736(95)00245-6</mixed-citation></ref><ref id="scirp.133123-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Mitroshina, E.V., Marasanova, E.A. and Vedunova, M.V. (2023) Functional Dimerization of Serotonin Receptors: Role in Health and Depressive Disorders. &lt;i&gt;Intern&lt;/i&gt;&lt;i&gt;a&lt;/i&gt;&lt;i&gt;tional Journal of Molecular Sciences&lt;/i&gt;, 24, Article 16416. &lt;br&gt;https://doi.org/10.3390/ijms242216416</mixed-citation></ref><ref id="scirp.133123-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Schappi, J.M. and Rasenick, M.M. (2022) G&amp;#945;&lt;sub&gt;s&lt;/sub&gt;, Adenyl Cyclase, and Their Relationship to the Diagnosis and Treatment of Depression. &lt;i&gt;Frontiers in Pharmacology&lt;/i&gt;, 13, Article 1012778. &lt;br&gt;https://doi.org/10.3389/fphar.2022.1012778</mixed-citation></ref><ref id="scirp.133123-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Singh, H., Wray, N., Schappi, J.M. and Rasenick, M.M. (2018) Disruption of Lipid-Raft Localised G&amp;#945;&lt;sub&gt;S&lt;/sub&gt;/Tubulin Complexes by Antidepressants: A Unique Feature of HDAC6 Inhibitors, SSRI and Tricyclic Compounds. &lt;i&gt;Neuropsychopharmacology&lt;/i&gt;, 43, 1481-1491. &lt;br&gt;https://doi.org/10.1038/s41386-018-0016-x</mixed-citation></ref><ref id="scirp.133123-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Hull, J.D. and Lyon, R.A. (2018) &lt;i&gt;In vitro&lt;/i&gt; Pharmacology of Ambroxol: Potential Serotonergic Sites of Action. &lt;i&gt;Life Sciences&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;197, 67-72. &lt;br&gt;https://doi.org/10.1016/j.lfs.2018.02.002</mixed-citation></ref><ref id="scirp.133123-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Coleman, J.A., Yang, D., Zhao, Z., Wen, P.C., Yoshioka, C., Tajkhorshid, E. and Gouaux, E. (2019) Serotonin Transporter-Ibogaine Complexes Illuminate Mechanisms of Inhibition and Transport. &lt;i&gt;Nature&lt;/i&gt;, 569, 141-145.&lt;br&gt;https://doi.org/10.1038/s41586-019-1135-1</mixed-citation></ref><ref id="scirp.133123-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Wu, C.-H., Chang, C.-S., Yang, Y.K., Shen, L.-H. and Yao, W.-J. (2017) Comparison of Brain Serotonin Transporter Using [I-123]-ADAM between Obese and Non-Obese Young Adults without an Eating Disorder. &lt;i&gt;PLOS ONE&lt;/i&gt;, 12, e0170886.&lt;br&gt;https://doi.org/10.1371/journal.pone.0170886</mixed-citation></ref><ref id="scirp.133123-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Oz, M., Libby, T., Kivell, B., Jaligam, V., Ramamoorthy, S. and Shippenberg, T.S. (2010) Real-Time, Spatially Resolved Analysis of Serotonin Transporter Activity and Regulation Using the Fluorescent Substrate, ASP&lt;sup&gt; &lt;/sup&gt;. &lt;i&gt;Journal of Neurochemistry&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;114, 1019-1029. &lt;br&gt;https://doi.org/10.1111/j.1471-4159.2010.06828.x</mixed-citation></ref><ref id="scirp.133123-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Launay, J.-M., Schneider, B., Loric, S., Da Prada, M. and Kellerman, O. (2006) Serotonin Transport and Serotonin Transporter-Mediated Antidepressant Recognition Are Controlled by 5-HT&lt;sub&gt;2B&lt;/sub&gt; Receptor Signaling in Serotonergic Neuronal Cells. &lt;i&gt;The FASEB Journal&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;20, 1843-1854. &lt;br&gt;https://doi.org/10.1096/fj.06-5724com</mixed-citation></ref><ref id="scirp.133123-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Gradisch, R., Schlogl, K., Lazzarin, E., Niello, M., Maier, J., Mayer, F.P., Alves da Silva, L., Skopec, S.M.C., Blakely, R.D., Sitte, H.H., Mihovilovic, M.D. and Stockner T. (2024) Ligand Coupling Mechanism of the Human Serotonin Transporter Differentiates Substrates from Inhibitors. &lt;i&gt;Nature Communications&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;15, Article No. 417. &lt;br&gt;https://doi.org/10.1038/s41467-023-44637-6</mixed-citation></ref><ref id="scirp.133123-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Blough, B.E., Landavazo, A., Decker, A.M., Partilla, J.S., Baumann, M.H. and Rothman, R.B. (2014) Interaction of Psychoactive Tryptamines with Biogenic Amine Transporters and Serotonin Receptor Subtypes. &lt;i&gt;Psychopharmacology&lt;/i&gt;, 231, 4135-4144. &lt;br&gt;https://doi.org/10.1007/s00213-014-3557-7</mixed-citation></ref><ref id="scirp.133123-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Lee, H.J., Tsang, V.W., Chai, B.S., Lin, M.C., Howard, A., Uy, C. and Elefante, J.O. (2023) Psilocybin&amp;#8217;s Potential Mechanisms in the Treatment of Depression: A Systematic Review. &lt;i&gt;Journal of Psychoactive Drugs&lt;/i&gt;, 29, 1-15. &lt;br&gt;https://doi.org/10.1080/02791072.2023.2223195</mixed-citation></ref><ref id="scirp.133123-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Bowman, M.A., Vitela, M., Clarke, K.M., Koek, W. and Daws, L.C. (2020) Serotonin Transporter and Plasma Membrane Monoamine Transporter Are Necessary for the Antidepressant-Like Effects of Ketamine in Mice. &lt;i&gt;International Journal of Molec&lt;/i&gt;&lt;i&gt;u&lt;/i&gt;&lt;i&gt;lar Sciences&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;21, Article 7581. &lt;br&gt;https://doi.org/10.3390/ijms21207581</mixed-citation></ref><ref id="scirp.133123-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Yamamoto, S., Ohba, H., Nishiyama, S., Harada, N., Kackiuchi, T., Tsukada, H. and Domino, E.F. (2013) Subanaesthetic Doses of Ketamine Transiently Decrease Serotonin Transporter Activity: A PET Study in Conscious Monkeys. &lt;i&gt;Neuropsych&lt;/i&gt;&lt;i&gt;o&lt;/i&gt;&lt;i&gt;pharmacology&lt;/i&gt;, 38, 2666-2674. &lt;br&gt;https://doi.org/10.1038/npp.2013.176</mixed-citation></ref><ref id="scirp.133123-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Zaytseva, A., Bouckova, E., Wiles, M.J., Wustrau, M.H., Schmidt, I.G., Medez-Vazquez, H., Khatri, L. and Kim, S. (2023) Ketamine&amp;#8217;s Rapid Antidepressant Effects Are Mediated by Ca&lt;sup&gt;2 &lt;/sup&gt;-Permeable AMPA Receptors. &lt;i&gt;eLife&lt;/i&gt;, 12, e86022. &lt;br&gt;https://doi.org/10.7554/eLife.86022</mixed-citation></ref><ref id="scirp.133123-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Suzuki, A., Hara, H. and Kimura, H. (2023) Role of the AMPA Receptor in Antidepressant Effects of Ketamine and Potential of AMPA Receptor Potentiators as a Novel Antidepressant. &lt;i&gt;Neuropharmacology&lt;/i&gt;, 222, Article 109308. &lt;br&gt;https://doi.org/10.1016/j.neuropharm.2022.109308</mixed-citation></ref><ref id="scirp.133123-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Kobayashi, N.H.C., Farias, S.V., Luz, D.A., Machado-Ferraro, K.M., Costa da Conceicao, B., Menezes da Silveira, C.C., Fernandes, L.M.P., de Carvalho Cartagenes, S., Ferreira, V.M.M., Fontes-Junior, E.A. and Maia, C.S.F. (2022) Ketamine Plus Alcohol: What We Know and What We Can Expect about This. &lt;i&gt;International Journal of Molecular Sciences&lt;/i&gt;, 23, Article 7800. &lt;br&gt;https://doi.org/10.3390/ijms23147800</mixed-citation></ref><ref id="scirp.133123-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Williams, W.R. (2018) Cell Signal Transduction; Hormones, Neurotransmitters and Therapeutic Drugs Relate to Purine Nucleotide Structure. &lt;i&gt;Journal of Receptors and Signal Transduction&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;38, 101-111. &lt;br&gt;https://doi.org/10.1080/10799893.2018.1431279</mixed-citation></ref><ref id="scirp.133123-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Choudhury, D., Autry, A.E., Tolias, K.F. and Krishnan, V. (2021) Ketamine: Neuroprotective or Neurotoxic? &lt;i&gt;Frontiers in Neuroscience&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;15, Article 672526.&lt;br&gt;https://doi.org/10.3389/fnins.2021.672526</mixed-citation></ref><ref id="scirp.133123-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Zanatta, L.M., Nascimento, F.C., Barros, S.V., Silva, G.R. Zugno, A.I., Netto, C.A. and Wyse, A.T. (2001) &lt;i&gt;In vivo&lt;/i&gt; and &lt;i&gt;In vitro&lt;/i&gt; Effect of Imipramine and Fluoxetine on Na&lt;sup&gt; &lt;/sup&gt;, K&lt;sup&gt; &lt;/sup&gt;-ATPase Activity in Synaptic Plasma Membranes from the Cerebral Cortex of Rats. &lt;i&gt;Brazilian Journal of Medical Biology Research&lt;/i&gt;, 34, 1265-1269. &lt;br&gt;https://doi.org/10.1590/S0100-879X2001001000005</mixed-citation></ref><ref id="scirp.133123-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Levey, J.S. and Epstein, S.E. (1969) Myocardial Adenyl Cyclase: Activation by Thyroid Hormones and Evidence for Two Adenyl Cyclase Systems. &lt;i&gt;The Journal of Clinical Investigation&lt;/i&gt;, 48, 1663-1669.</mixed-citation></ref><ref id="scirp.133123-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Incerpi, S., Gionfra, F., De Luca, R., Candelotti, E., De Vito, P., Precario, Z.A., Leone, S., Gnocchi, D., Rossi, M., Caruso, F., Scapin, S., Davis, P.J., Lin, H.Y., Affabris, E. and Pedersen, J.Z. (2022) Extranuclear Effects of Thyroid Hormones and Analogs during Development: An Old Mechanism with Emerging Roles. &lt;i&gt;Frontiers in Endocrinology&lt;/i&gt;, 13, Article 961744. &lt;br&gt;https://doi.org/10.3389/fendo.2022.961744</mixed-citation></ref><ref id="scirp.133123-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Hernandez-R, J. (1992) Na&lt;sup&gt; &lt;/sup&gt;/K&lt;sup&gt; &lt;/sup&gt;-ATPase Regulation by Neurotransmitters. &lt;i&gt;Neur&lt;/i&gt;&lt;i&gt;o&lt;/i&gt;&lt;i&gt;chemistry International&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;20, 1-10. &lt;br&gt;https://doi.org/10.1016/0197-0186(92)90119-C</mixed-citation></ref><ref id="scirp.133123-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Schmid, D., Ecker, G., Kopp, S, Hitzler, M. and Chiba, P. (1999) Structure-Activity Relationship Studies of Propafenone Analogs Based on P-Glycoprotein ATPase Activity Measurements. &lt;i&gt;Biochemical Pharmacology&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;58, 1447-1456.&lt;br&gt;https://doi.org/10.1016/S0006-2952(99)00229-4</mixed-citation></ref><ref id="scirp.133123-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Andersson, T.L.G., Zygmunt, P. and Vinge, E. (1991) Some Substances with Proposed Digitalis-Like Effects Evaluated in Platelet Functions Sensitive for Cardiac Glycosides. &lt;i&gt;General Pharmacology&lt;/i&gt;: &lt;i&gt;The Vascular System&lt;/i&gt;, 22, 749-753.&lt;br&gt;https://doi.org/10.1016/0306-3623(91)90090-S</mixed-citation></ref><ref id="scirp.133123-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Fuerstenwerth, H. (2014) On the Differences between Ouabain and Digitalis Glycosides. &lt;i&gt;American Journal of Therapeutics&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;21, 35-42.&lt;br&gt;https://doi.org/10.1097/MJT.0b013e318217a609</mixed-citation></ref><ref id="scirp.133123-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Song, H., Karashima, E., Hamlin, J.M. and Blaustein, M.P. (2014) Ouabain-Digoxin Antagonism in Rat Arteries and Neurones. &lt;i&gt;Journal of Physiology&lt;/i&gt;, 592, 941-969. &lt;br&gt;https://doi.org/10.1113/jphysiol.2013.266866</mixed-citation></ref><ref id="scirp.133123-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Pratt, R.D., Brickman, C.R., Cottrill, C.L., Shapiro, J.I. and Liu, J. (2018) The Na/K-ATPase Signaling: From Specific Ligands to General Reactive Oxygen Species. &lt;i&gt;I&lt;/i&gt;&lt;i&gt;n&lt;/i&gt;&lt;i&gt;ternational Journal of Molecular Sciences&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;19, Article 2600. &lt;br&gt;https://doi.org/10.3390/ijms19092600</mixed-citation></ref><ref id="scirp.133123-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Valvassori, S.S., Dal-Pont, G.C., Resende, W.R. Varela, R.B., Lopes-Borges, J., Carro, J.H. and Quevedo, J. (2019) Validation of the Animal Model of Bipolar Disorder Induced by Ouabain: Face, Construct and Predictive Perspectives. &lt;i&gt;Translational Psychiatry&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;9, Article No. 158. &lt;br&gt;https://doi.org/10.1038/s41398-019-0494-6</mixed-citation></ref><ref id="scirp.133123-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Malhi, G.S., Tanious, M., Das, P., Coulston, C. and Berk, M. (2013) Potential Mechanisms of Action of Lithium in Bipolar Disorder. Current Understanding. &lt;i&gt;CNS &lt;/i&gt;&lt;i&gt;Drugs&lt;/i&gt;, 27, 135-153. &lt;br&gt;https://doi.org/10.1007/s40263-013-0039-0</mixed-citation></ref><ref id="scirp.133123-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Qaswal, A.B. (2020) Lithium Stabilises the Mood of Bipolar Patients by Depolarising the Neuronal Membrane via Quantum Tunneling through the Sodium Channels. &lt;i&gt;Clinical Psychopharmacology and Neuroscience&lt;/i&gt;, 18, 214-218.&lt;br&gt;https://doi.org/10.9758/cpn.2020.18.2.214</mixed-citation></ref><ref id="scirp.133123-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Bahremand, A., Nasrabady, S.E., Ziai, P., Rahimian, R., Hedayat, T., Payandemehr, B. and Dehpour, A.H. (2010) Involvement of Nitric Oxide-cGMP Pathway in the Anticonvulsant Effects of Lithium Chloride on PTZ-Induced Seizure in Mice. &lt;i&gt;Ep&lt;/i&gt;&lt;i&gt;i&lt;/i&gt;&lt;i&gt;lepsy Research&lt;/i&gt;, 89, 295-302. &lt;br&gt;https://doi.org/10.1016/j.eplepsyres.2010.02.001</mixed-citation></ref><ref id="scirp.133123-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Walia, V., Garg, C. and Garg, M. (2019) NO-sGC-cGMP Signaling Influence the Anxiolytic like Effect of Lithium in Mice in Light and Dark Box and Elevated Plus Maze. &lt;i&gt;Brain Research&lt;/i&gt;, 1704, 114-126. &lt;br&gt;https://doi.org/10.1016/j.brainres.2018.10.002</mixed-citation></ref><ref id="scirp.133123-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Oz, M., Isaev, D., Lorke, D.E., Hasan, M., Petrolanu, G. and Shippenberg, T.S. (2012) Methylene Blue Inhibits Function of the 5-HT Transporter. &lt;i&gt;British Journal of Pharmacology&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;166,168-176. &lt;br&gt;https://doi.org/10.1111/j.1476-5381.2011.01462.x</mixed-citation></ref><ref id="scirp.133123-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Erb, S.J., Schipp, J.M. and Rasenick, M.M. (2016) Antidepressants Accumulate in Lipid Rafts Independent of Monoamine Transporters to Modulate Redistribution of the G Protein, G&amp;#945;&lt;sub&gt;S&lt;/sub&gt;. &lt;i&gt;The Journal of Biological Chemistry&lt;/i&gt;, 291, 19725-19733.&lt;br&gt;https://doi.org/10.1074/jbc.M116.727263</mixed-citation></ref><ref id="scirp.133123-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Pejchal, T., Foley, M.A., Kosofsky, B.E. and Waeber, C. (2002) Chronic Fluoxetine Treatment Selectively Uncouples Raphe 5-HT&lt;sub&gt;1A&lt;/sub&gt; Receptors as Measured by [&lt;sup&gt;35&lt;/sup&gt;S]-GTP&amp;#947;S Autoradiography. &lt;i&gt;British Journal of Pharmacology&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;135, 1115-1122.&lt;br&gt;https://doi.org/10.1038/sj.bjp.0704555</mixed-citation></ref><ref id="scirp.133123-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Latorraca, N.R., Venkatakrishnan, A.J. and Dror, R.O. (2017) GPCR Dynamics: Structures in Motion. &lt;i&gt;Chemical Reviews&lt;/i&gt;, 117, 139-155.&lt;br&gt;https://doi.org/10.1021/acs.chemrev.6b00177</mixed-citation></ref></ref-list></back></article>